Taiwan Liposome Sees Generic Of J&J Cancer Drug In Europe Next Year
This article was originally published in PharmAsia News
Executive Summary
Taiwan Liposome said it expects its Doxisome (liposomal) generic of a treatment for breast and ovarian cancer to be on Europe's $200 million market within the next nine months and then the larger U.S. market.
You may also be interested in...
US Startup Ignites Consumer Health Portfolio Build With North American Rights To ThermaCare
Bridges Consumer Healthcare launched by former Sanofi executives gets its first brand by acquiring North American rights to Pfizer’s ThermaCare HeatWraps brand. Pfizer divested the brand so European regulators would give antitrust clearance to its consumer JV with GSK.
US FDA Critic Leads House Appropriators, Consumer Health Ally Heads Energy And Commerce
Rosa DeLauro prevails over fellow Democrats Debbie Wasserman Schultz and Marcy Kaptur for Appropriations chair. Frank Pallone gets unanimous support from Democrats to continue as Energy and Commerce chair.
CMS Final Medicare Outpatient Rule Gives Patients More Surgical Site Choices, At Lower Costs
The US Medicare agency is offering more lower-cost alternative sites for 2021 surgical procedures to be covered under its OPPS and ASC final rule.
Need a specific report? 1000+ reports available
Buy Reports